Dimerix Bioscience

Dimerix Bioscience is a publicly held, unlisted clinical-stage drug discovery and development company and a wholly owned subsidiary of Sun Biomedical Limited (ASX: SBN Sun Biomedical Home Page). Dimerix’s primary clinical program is a Phase 2 study of DMX-200 for chronic kidney disease, located in Melbourne. This study repurposes an existing molecule at its core, and based on successful outcomes from the study, Dimerix intends to pursue a product registration pathway for orphan indications. The study has commenced under the supervision of Professor Power at Austin Hospital and is currently recruiting patients.